78 related articles for article (PubMed ID: 12455058)
1. The prognostic impact of cytokeratin-positive cells in bone marrow of patients with localized prostate cancer.
Lilleby W; Nesland JM; Fosså SD; Torlakovic G; Waehre H; Kvalheim G
Int J Cancer; 2003 Jan; 103(1):91-6. PubMed ID: 12455058
[TBL] [Abstract][Full Text] [Related]
2. Urokinase-plasminogen-activator receptor expression in disseminated tumour cells in the bone marrow and peripheral blood of patients with clinically localized prostate cancer.
Thomas C; Wiesner C; Melchior SW; Schmidt F; Gillitzer R; Thüroff JW; Pfitzenmaier J
BJU Int; 2009 Jul; 104(1):29-34. PubMed ID: 19154451
[TBL] [Abstract][Full Text] [Related]
3. Impact of disseminated tumor cells in bone marrow at diagnosis in patients with nonmetastatic prostate cancer treated by definitive radiotherapy.
Berg A; Berner A; Lilleby W; Bruland ØS; Fosså SD; Nesland JM; Kvalheim G
Int J Cancer; 2007 Apr; 120(8):1603-9. PubMed ID: 17230512
[TBL] [Abstract][Full Text] [Related]
4. A summary of two clinical studies on tumor cell dissemination in primary and metastatic breast cancer: methods, prognostic significance and implication for alternative treatment protocols (Review).
Kasimir-Bauer S; Oberhoff C; Schindler AE; Seeber S
Int J Oncol; 2002 May; 20(5):1027-34. PubMed ID: 11956600
[TBL] [Abstract][Full Text] [Related]
5. Disseminated tumor cells and their prognostic significance in nonmetastatic prostate cancer patients.
Lilleby W; Stensvold A; Mills IG; Nesland JM
Int J Cancer; 2013 Jul; 133(1):149-55. PubMed ID: 23280694
[TBL] [Abstract][Full Text] [Related]
6. Patterns of disease recurrence influenced by hematogenous tumor cell dissemination in patients with cervical carcinoma of the uterus.
Janni W; Hepp F; Strobl B; Rack B; Rjosk D; Kentenich C; Schindlbeck C; Hantschmann P; Pantel K; Sommer H; Braun S
Cancer; 2003 Jan; 97(2):405-11. PubMed ID: 12518364
[TBL] [Abstract][Full Text] [Related]
7. Does the immunocytochemical detection of epithelial cells in bone marrow (micrometastasis) influence the time to biochemical relapse after radical prostatectomy?
Weckermann D; Wawroschek F; Krawczak G; Haude KH; Harzmann R
Urol Res; 1999 Aug; 27(4):285-90. PubMed ID: 10460901
[TBL] [Abstract][Full Text] [Related]
8. Detection and prognostic value of cytokeratin positive tumor cells in bone marrow of patients with renal cell carcinoma.
Buchner A; Riesenberg R; Kotter I; Crispin A; Hofstetter A; Oberneder R
J Urol; 2003 Nov; 170(5):1747-51. PubMed ID: 14532768
[TBL] [Abstract][Full Text] [Related]
9. Disseminated tumor cells in bone marrow following definitive radiotherapy for intermediate or high-risk prostate cancer.
Berg A; Bruland ØS; Fosså SD; Nesland JM; Berner A; Schirmer C; Lilleby W
Prostate; 2008 Nov; 68(15):1607-14. PubMed ID: 18655095
[TBL] [Abstract][Full Text] [Related]
10. Disseminated cytokeratin positive tumor cells in the bone marrow of patients with prostate cancer: detection and prognostic value.
Weckermann D; Müller P; Wawroschek F; Harzmann R; Riethmüller G; Schlimok G
J Urol; 2001 Aug; 166(2):699-703. PubMed ID: 11458120
[TBL] [Abstract][Full Text] [Related]
11. Disseminated tumor cells in bone marrow of patients with transitional cell carcinoma: immunocytochemical detection and correlation with established prognostic indicators.
Hofmann T; Riesenberg R; Buchner A; Zimmermann W; Hofstetter A; Oberneder R
J Urol; 2003 Apr; 169(4):1303-7. PubMed ID: 12629348
[TBL] [Abstract][Full Text] [Related]
12. Her2 expression on disseminated tumor cells from bone marrow of breast cancer patients.
Becker S; Becker-Pergola G; Fehm T; Wallwiener D; Solomayer EF
Anticancer Res; 2005; 25(3B):2171-5. PubMed ID: 16158960
[TBL] [Abstract][Full Text] [Related]
13. Survival of tumor cells in stem cell preparations and bone marrow of patients with high-risk or metastatic breast cancer after receiving dose-intensive or high-dose chemotherapy.
Kasimir-Bauer S; Mayer S; Bojko P; Borquez D; Neumann R; Seeber S
Clin Cancer Res; 2001 Jun; 7(6):1582-9. PubMed ID: 11410494
[TBL] [Abstract][Full Text] [Related]
14. Isolated tumor cells in bone marrow three years after diagnosis in disease-free breast cancer patients predict unfavorable clinical outcome.
Wiedswang G; Borgen E; Kåresen R; Qvist H; Janbu J; Kvalheim G; Nesland JM; Naume B
Clin Cancer Res; 2004 Aug; 10(16):5342-8. PubMed ID: 15328170
[TBL] [Abstract][Full Text] [Related]
15. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
[TBL] [Abstract][Full Text] [Related]
16. The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence.
Janni W; Rack B; Schindlbeck C; Strobl B; Rjosk D; Braun S; Sommer H; Pantel K; Gerber B; Friese K
Cancer; 2005 Mar; 103(5):884-91. PubMed ID: 15666325
[TBL] [Abstract][Full Text] [Related]
17. Does the immunocytochemical detection of epithelial cells in bone marrow (micrometastasis) influence the time to biochemical relapse after radical prostatectomy?
Weckermann D; Wawroschek F; Krawczak G; Haude KH; Harzmann R
Urol Res; 1999 Oct; 27(5):285-90. PubMed ID: 10644227
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of cytokeratin-positive bone marrow cells of gastric cancer patients.
Gretschel S; Schick C; Schneider U; Estevez-Schwarz L; Bembenek A; Schlag PM
Ann Surg Oncol; 2007 Feb; 14(2):373-80. PubMed ID: 17080240
[TBL] [Abstract][Full Text] [Related]
19. Prostate-specific antigen for pretreatment prediction and posttreatment evaluation of outcome after definitive irradiation for prostate cancer.
Kuban DA; el-Mahdi AM; Schellhammer PF
Int J Radiat Oncol Biol Phys; 1995 May; 32(2):307-16. PubMed ID: 7538499
[TBL] [Abstract][Full Text] [Related]
20. Monitoring of disseminated tumor cells in bone marrow in high-risk breast cancer patients treated with high-dose chemotherapy.
Drageset V; Nesland JM; Erikstein B; Skovlund E; Sommer H; Anker G; Wist E; Lundgren S; Bergh J; Kvalheim G
Int J Cancer; 2006 Jun; 118(11):2877-81. PubMed ID: 16381016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
